Skip to main content
SpringerLink
Log in

Cannabis-Based Medicines — GW Pharmaceuticals

High CBD, High THC, Medicinal Cannabis — GW Pharmaceuticals, THC:CBD

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Bayer AG, GW Pharmaceuticals plc. Bayer and GW Pharma-ceuticals announce marketing agreement on pioneering new cannabis-based treatment. Media Release: 21 May 2003. Available from URL: http://www.bayer.com

  2. Guy GW, Flint ME, Robson PJ, et al. A phase one study of sublingual cannabis-based medicine extract. Journal of Pharmacy and Pharmacology 52 (Suppl.): 294, Sep 2000

    Google Scholar 

  3. GW Pharmaceuticals plc. GW Announces Positive Results From Each of Four Phase Three Clinical Trials. Media Release: 5 Nov 2002. Available from URL: http://www.gwpharm.com

  4. Hart EM, Doherty WL, Sharpe P, et al. An open-labelled, dose-finding study of the analgesic and side-effects of a cannabis-based medicine extract in a model of postoperative pain. British Journal of Anaesthesia 88: 321P, Feb 2002

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cannabis-Based Medicines — GW Pharmaceuticals. Drugs R&D 4, 306–309 (2003). https://doi.org/10.2165/00126839-200304050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304050-00005

Keywords

Search

Navigation